Longitude Venture Partners II, L.P. is 10% at Aimmune Therapeutics, Inc. (AIMT). They have made 1 open-market trade across 1 company since 2026, most recently 2026-02-04.
CIK 0001527510
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KALA | 2,055,946 | $386K |
| TCDA | 2,888,155 | $312K |
| AIMT | 7,276 | $251K |
| Total | $949K |
Shares reported on the most recent Form 4, priced at the 2018-07-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPID | SELL | 2026-02-04 | 2026-02-06 | $3.88 | $190K | +2.6% | +8.5% | -33.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.